FDA Approves First Antisense Drug for Hepatitis B
The regulatory agency cleared GSK's Hibsago for the treatment of adults with chronic hepatitis B who lack cirrhosis.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you trust that new medical treatments for chronic conditions represent genuine long-term health improvements?
The FDA has granted approval to Hibsago, a new injectable antisense oligonucleotide developed by GSK for treating chronic hepatitis B in adults. This therapy is the first of its kind to be approved for patients who do not have cirrhosis and are currently on antiviral treatment.
Why it matters
Chronic hepatitis B is a persistent liver infection that carries significant long-term risks, including the development of cirrhosis and liver cancer. Providing a new mechanism to address the virus offers a potential pathway for patients to achieve sustained viral control.
Eligible patients must have hepatitis B surface antigen levels of 3,000 IU/mL or less. The treatment regimen involves injections administered for a duration of 24 weeks alongside existing antiviral medicine.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
GSK plc
GSK is a global biopharmaceutical company that focuses on research and development in areas including infectious diseases, immunology, and oncology.
The details
Hibsago functions by targeting the genetic instructions the virus uses to replicate itself and produce viral proteins. Patients must have been on existing HBV antiviral therapy for at least six months to qualify for the treatment, which includes a boxed warning for potential liver reactions and low platelet counts.
Timeline
October 20, 2026: The FDA officially approved Hibsago.
The Big Picture
This approval aligns with the FDA's Accelerated Approval pathway for infectious disease treatments by fast-tracking a novel therapeutic mechanism. It represents a significant shift from traditional antiviral maintenance toward genetic-based viral suppression.
Patients who meet the strict antigen level requirements may now have an alternative option to supplement their current antiviral regimen. Users should discuss potential side effects, such as injection site reactions and liver-related risks, with their healthcare providers.
The takeaway
This approval marks a milestone in genetic medicine by introducing a new way to suppress viral replication. Patients should continue working with their physicians to evaluate their eligibility based on specific antigen levels and medical history.
Further reading
Learn more about advancements in pharmaceutical development in the United States biotech section.
More information
Review the full FDA official drug approval announcement for detailed patient guidelines.
Live Poll
Do you trust that new medical treatments for chronic conditions represent genuine long-term health improvements?
